CD19 and non-Hodgkin lymphoma: Having confirmed the expression of CAR19 in primary human T cells, we next evaluated its anti-leukemic effects on CD19+ cancer cell lines Raji (NHL), Reh (ALL), or with CD19‒ control lines K562 or 293T (Fig. 1C–F, respectively).